Although KEYNOTE-048 validated pembrolizumab in PD-L1-high HNSCC, our patient with EBV-driven NPC required a tailored approach, prioritizing EBV DNA monitoring over PD-L1 status. Here, CD274 is linked to nasopharyngeal carcinoma.